HUP0402396A3 - Ophtalmic compositions comprising ascomycin - Google Patents

Ophtalmic compositions comprising ascomycin

Info

Publication number: HUP0402396A3
Authority: HU; Hungary
Prior art keywords: ophtalmic; ascomycin; compositions; ophtalmic compositions
Prior art date: 2001-08-23

Application number

HU0402396A

Other languages

English (en)

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-23

Filing date

2002-08-22

Publication date

2005-12-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23219986&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0402396(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-08-22 Application filed by Novartis Ag filed Critical Novartis Ag

2005-09-28 Publication of HUP0402396A2 publication Critical patent/HUP0402396A2/hu

2005-12-28 Publication of HUP0402396A3 publication Critical patent/HUP0402396A3/hu

Links

ZDQSOHOQTUFQEM-PKUCKEGBSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C\C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-PKUCKEGBSA-N 0.000 title 1
ZDQSOHOQTUFQEM-XCXYXIJFSA-N ascomycin Natural products CC[C@H]1C=C(C)C[C@@H](C)C[C@@H](OC)[C@H]2O[C@@](O)([C@@H](C)C[C@H]2OC)C(=O)C(=O)N3CCCC[C@@H]3C(=O)O[C@H]([C@H](C)[C@@H](O)CC1=O)C(=C[C@@H]4CC[C@@H](O)[C@H](C4)OC)C ZDQSOHOQTUFQEM-XCXYXIJFSA-N 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

HU0402396A 2001-08-23 2002-08-22 Ophtalmic compositions comprising ascomycin HUP0402396A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US31444801P	2001-08-23	2001-08-23
PCT/EP2002/009408 WO2003017990A2 (en)	2001-08-23	2002-08-22	Ophthalmic composition comprising an ascomycin

Publications (2)

Publication Number	Publication Date
HUP0402396A2 HUP0402396A2 (hu)	2005-09-28
HUP0402396A3 true HUP0402396A3 (en)	2005-12-28

Family

ID=23219986

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU0402396A HUP0402396A3 (en)	2001-08-23	2002-08-22	Ophtalmic compositions comprising ascomycin

Country Status (27)

Country	Link
US (2)	US20030050255A1 (hu)
EP (1)	EP1420787B8 (hu)
JP (1)	JP2005501105A (hu)
KR (2)	KR20100089108A (hu)
CN (1)	CN100366251C (hu)
AR (1)	AR035293A1 (hu)
AT (1)	ATE452638T1 (hu)
AU (1)	AU2002331172B2 (hu)
BR (1)	BR0211972A (hu)
CA (1)	CA2457034C (hu)
CO (1)	CO5560568A2 (hu)
DE (1)	DE60234840D1 (hu)
EC (1)	ECSP044981A (hu)
ES (1)	ES2337130T3 (hu)
HU (1)	HUP0402396A3 (hu)
IL (1)	IL160374A0 (hu)
MX (1)	MXPA04001646A (hu)
MY (1)	MY157377A (hu)
NO (1)	NO20040775L (hu)
NZ (1)	NZ531224A (hu)
PE (1)	PE20030311A1 (hu)
PL (1)	PL208685B1 (hu)
PT (1)	PT1420787E (hu)
RU (1)	RU2313344C2 (hu)
TW (1)	TWI324925B (hu)
WO (1)	WO2003017990A2 (hu)
ZA (1)	ZA200400772B (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7354574B2 (en)	2002-11-07	2008-04-08	Advanced Ocular Systems Limited	Treatment of ocular disease
BE1015610A3 (nl) *	2003-07-17	2005-06-07	Corrutech Nv	Verbeterde lijm en werkwijze voor het vervaardigen ervan.
US7083802B2 (en) *	2003-07-31	2006-08-01	Advanced Ocular Systems Limited	Treatment of ocular disease
KR20060085246A (ko)	2003-09-18	2006-07-26	마커사이트, 인코포레이티드	경공막 전달
US7087237B2 (en) *	2003-09-19	2006-08-08	Advanced Ocular Systems Limited	Ocular solutions
US7083803B2 (en)	2003-09-19	2006-08-01	Advanced Ocular Systems Limited	Ocular solutions
DK1848431T3 (en)	2005-02-09	2016-04-18	Santen Pharmaceutical Co Ltd	LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
EP1904056B1 (en)	2005-07-18	2009-04-29	Minu, L.L.C.	Use of a macrolide to restore corneal sensation
KR20140093764A (ko)	2006-02-09	2014-07-28	산텐 세이야꾸 가부시키가이샤	안정한 제제와 그 제조 및 사용 방법
ES2563288T3 (es)	2006-03-23	2016-03-14	Santen Pharmaceutical Co., Ltd	Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
NZ582188A (en) *	2007-07-11	2012-03-30	Pfizer	Pharmaceutical compositions and methods of treating dry eye disorders
EP2278999B1 (en)	2008-04-21	2025-01-29	Dompé farmaceutici S.p.A.	Auris formulations for treating otic diseases and conditions
US11969501B2 (en)	2008-04-21	2024-04-30	Dompé Farmaceutici S.P.A.	Auris formulations for treating otic diseases and conditions
US8030297B2 (en)	2008-05-14	2011-10-04	Otonomy, Inc.	Controlled release corticosteroid compositions and methods for the treatment of OTIC disorders
US8648119B2 (en)	2008-05-23	2014-02-11	Otonomy, Inc.	Controlled release immunomodulator compositions and methods for the treatment of otic disorders
US8846770B2 (en)	2008-06-18	2014-09-30	Otonomy, Inc.	Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
US8349353B2 (en)	2008-06-27	2013-01-08	Otonomy, Inc.	Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
WO2010011466A2 (en)	2008-06-27	2010-01-28	Otonomy, Inc.	Controlled-release cns modulating compositions and methods for the treatment of otic disorders
US8496957B2 (en)	2008-07-21	2013-07-30	Otonomy, Inc	Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8318817B2 (en)	2008-07-21	2012-11-27	Otonomy, Inc.	Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US8399018B2 (en)	2008-07-21	2013-03-19	Otonomy, Inc.	Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
EP2306975A4 (en)	2008-07-21	2012-10-31	Otonomy Inc	COMPOSITIONS WITH A TAXED RELEASE FOR MODULATING THE EARM STRUCTURE AND THE BORN IMMUNE SYSTEM, AND METHODS OF TREATING EAR OR DISEASE
CA2751761A1 (en)	2008-10-22	2010-04-29	House Ear Institute	Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor
JP2016534121A (ja)	2013-08-27	2016-11-04	オトノミ—，インク．	小児の耳の病気の処置
US20200155449A1 (en)	2015-11-16	2020-05-21	Medincell	Method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
EP3512513A4 (en)	2016-09-16	2020-04-15	Otonomy, Inc.	OTIC GEL FORMULATIONS FOR THE TREATMENT OF EXTERNAL OTITIS
JP7699426B2 (ja) *	2018-11-30	2025-06-27	ロート製薬株式会社	光線による障害からの細胞保護用眼科組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0459148B1 (en) *	1990-05-29	1996-01-03	Ocular Research Of Boston Inc.	Dry eye treatment composition
US5247076A (en) *	1991-09-09	1993-09-21	Merck & Co., Inc.	Imidazolidyl macrolides having immunosuppressive activity
EP0551626A1 (en) *	1991-12-19	1993-07-21	LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d.	Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
US5302584A (en) *	1992-10-13	1994-04-12	American Home Products Corporation	Carbamates of rapamycin
JPH06345646A (ja) *	1993-06-08	1994-12-20	Fujisawa Pharmaceut Co Ltd	ローション剤
CN100335063C (zh) *	1994-10-26	2007-09-05	诺瓦蒂斯有限公司	药物组合物
AR004480A1 (es) *	1995-04-06	1998-12-16	Amico Derin C D	Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
EP0978288A4 (en) *	1997-04-11	2006-07-12	Astellas Pharma Inc	DRUG COMPOSITION
CZ287497B6 (cs) *	1997-12-30	2000-12-13	Galena, A. S.	Topické oční přípravky s imunosupresivními látkami
WO2000066122A1 (en) *	1999-04-30	2000-11-09	Sucampo Ag	Use of macrolide compounds for the treatment of dry eye

2002
- 2002-08-21 TW TW091118911A patent/TWI324925B/zh not_active IP Right Cessation
- 2002-08-21 AR ARP020103137A patent/AR035293A1/es unknown
- 2002-08-22 RU RU2004108463/15A patent/RU2313344C2/ru not_active IP Right Cessation
- 2002-08-22 CA CA2457034A patent/CA2457034C/en not_active Expired - Fee Related
- 2002-08-22 KR KR1020107014068A patent/KR20100089108A/ko not_active Abandoned
- 2002-08-22 DE DE60234840T patent/DE60234840D1/de not_active Expired - Lifetime
- 2002-08-22 MY MYPI20023102A patent/MY157377A/en unknown
- 2002-08-22 BR BR0211972-2A patent/BR0211972A/pt active Search and Examination
- 2002-08-22 AT AT02767419T patent/ATE452638T1/de active
- 2002-08-22 ES ES02767419T patent/ES2337130T3/es not_active Expired - Lifetime
- 2002-08-22 WO PCT/EP2002/009408 patent/WO2003017990A2/en not_active Ceased
- 2002-08-22 IL IL16037402A patent/IL160374A0/xx unknown
- 2002-08-22 PT PT02767419T patent/PT1420787E/pt unknown
- 2002-08-22 HU HU0402396A patent/HUP0402396A3/hu unknown
- 2002-08-22 PE PE2002000808A patent/PE20030311A1/es not_active Application Discontinuation
- 2002-08-22 CN CNB028164466A patent/CN100366251C/zh not_active Expired - Fee Related
- 2002-08-22 JP JP2003522510A patent/JP2005501105A/ja active Pending
- 2002-08-22 PL PL367459A patent/PL208685B1/pl not_active IP Right Cessation
- 2002-08-22 NZ NZ531224A patent/NZ531224A/en not_active IP Right Cessation
- 2002-08-22 AU AU2002331172A patent/AU2002331172B2/en not_active Ceased
- 2002-08-22 KR KR10-2004-7002458A patent/KR20040030157A/ko not_active Ceased
- 2002-08-22 MX MXPA04001646A patent/MXPA04001646A/es active IP Right Grant
- 2002-08-22 EP EP02767419A patent/EP1420787B8/en not_active Expired - Lifetime
- 2002-08-23 US US10/227,086 patent/US20030050255A1/en not_active Abandoned
2004
- 2004-01-30 ZA ZA200400772A patent/ZA200400772B/en unknown
- 2004-02-17 NO NO20040775A patent/NO20040775L/no not_active Application Discontinuation
- 2004-02-18 EC EC2004004981A patent/ECSP044981A/es unknown
- 2004-02-18 CO CO04013810A patent/CO5560568A2/es not_active Application Discontinuation
2010
- 2010-11-30 US US12/955,950 patent/US20110071186A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ATE452638T1 (de)	2010-01-15
PE20030311A1 (es)	2003-05-08
CN100366251C (zh)	2008-02-06
MY157377A (en)	2016-06-15
ES2337130T3 (es)	2010-04-21
IL160374A0 (en)	2004-07-25
CO5560568A2 (es)	2005-09-30
WO2003017990A2 (en)	2003-03-06
EP1420787A2 (en)	2004-05-26
AR035293A1 (es)	2004-05-05
TWI324925B (en)	2010-05-21
MXPA04001646A (es)	2004-05-31
PL367459A1 (en)	2005-02-21
KR20040030157A (ko)	2004-04-08
BR0211972A (pt)	2004-09-21
KR20100089108A (ko)	2010-08-11
EP1420787B8 (en)	2010-09-01
RU2004108463A (ru)	2005-05-10
HUP0402396A2 (hu)	2005-09-28
EP1420787B1 (en)	2009-12-23
WO2003017990A3 (en)	2003-08-28
DE60234840D1 (de)	2010-02-04
PT1420787E (pt)	2010-03-01
ECSP044981A (es)	2004-04-28
CA2457034A1 (en)	2003-03-06
ZA200400772B (en)	2004-10-11
AU2002331172B2 (en)	2005-12-01
US20110071186A1 (en)	2011-03-24
RU2313344C2 (ru)	2007-12-27
CA2457034C (en)	2010-07-27
PL208685B1 (pl)	2011-05-31
NO20040775L (no)	2004-02-17
US20030050255A1 (en)	2003-03-13
CN1545414A (zh)	2004-11-10
JP2005501105A (ja)	2005-01-13
NZ531224A (en)	2005-09-30
HK1065961A1 (en)	2005-03-11

Legal Events

Date	Code	Title	Description
2011-05-30	FD9A	Lapse of provisional protection due to non-payment of fees

Publication	Publication Date	Title
HUP0402396A3 (en)	2005-12-28	Ophtalmic compositions comprising ascomycin
AU2002362122A8 (en)	2003-06-23	Elastomeric compositions
PL367134A1 (en)	2005-02-21	Novel composition
IL163657A0 (en)	2005-12-18	Ophthalmic composition comprising ascomycin
GB0114069D0 (en)	2001-08-01	Composition
GB0200763D0 (en)	2002-02-27	Compositions
DE60212707D1 (en)	2006-08-03	Optische phasenmodulation
GB0105622D0 (en)	2001-04-25	Compositions
EG23126A (en)	2004-04-28	Novel fungicial compositions
HUP0600303A2 (en)	2006-07-28	Pentafluorpropane based compositions
GB0114532D0 (en)	2001-08-08	Novel compositions
GB0122113D0 (en)	2001-10-31	Composition
GB0115679D0 (en)	2001-08-22	Composition
GB0117305D0 (en)	2001-09-05	Composition
GB0103328D0 (en)	2001-03-28	Compositions
EP1366758A4 (en)	2005-07-20	NEW OPHTHALMIC COMPOSITIONS
AU2003259301A8 (en)	2004-02-16	Ophtalmic compositions
GB0130369D0 (en)	2002-02-06	Hydrogel compositions
SI1482936T1 (sl)	2007-04-30	Oftalmicni sestavek, ki vkljucuje askomicin
GB0107904D0 (en)	2001-05-23	Novel compositions
GB0114314D0 (en)	2001-08-01	Novel compositions
GB0119469D0 (en)	2001-10-03	Novel compositions
GB0112345D0 (en)	2001-07-11	Compositions
GB0101392D0 (en)	2001-03-07	Compositions
GB0101391D0 (en)	2001-03-07	Compositions